Technology
Health
Biotechnology
Magenta Therapeutics
$16.569876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$16.56
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.25 (1.53%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell MGTA and other stocks, options, ETFs, and crypto commission-free!
About
Magenta Therapeutics, Inc. Common Stock, also called Magenta Therapeutics, is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. Read More It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.
Employees
—
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
556.12M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
139.21K
High Today
$17.30
Low Today
$16.22
Open Price
$16.22
Volume
132.38K
52 Week High
$21.00
52 Week Low
$5.31
Collections
Technology
Health
Biotechnology
Medical
Therapy
2018 IPO
US
North America
News
Yahoo FinanceMay 6
Magenta Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics, Inc. (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the closing of its previously announced public offering of 4,887,500 shares of its common stock, including 637,500 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $13.25 per share. The tota...
Price Paid on Robinhood
22% Higher
Right Now
52 Week Low
$5.31
Average Price Paid
$13.62
52 Week High
$21.00
Earnings
-$0.67
-$0.59
-$0.52
-$0.44
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.57 per share
Actual
-$0.44 per share